A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterium Modified Dextromethorphan Hydrobromide/Quinidine Sulfate) as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterium Modified Dextromethorphan Hydrobromide/Quinidine Sulfate) as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2017

At a glance

  • Drugs Deudextromethorphan (Primary)
  • Indications Major depressive disorder
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Avanir Pharmaceuticals
  • Most Recent Events

    • 11 May 2017 Status changed from recruiting to completed.
    • 16 Nov 2015 According to a company media release, Avanir Pharmaceuticals expects to complete enrolment in this study in 2015.
    • 29 Jan 2015 Planned End Date changed from 1 Jul 2017 to 1 Apr 2016 as reported by ClinicalTrails.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top